Thus, we propose that targeting IFN-driven microangiopathy prior to the onset of diffuse brain disease may represent an important neuroprotective strategy in AGS and cerebral interferonopathies. The gene discussed is IFNA1; the disease is Aicardi-Goutieres syndrome.